STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in approximately 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:STAA
Previous Symbol
CUSIP85231230
Phone626-303-7902
Debt
Debt-to-Equity Ratio0.01
Current Ratio5.35
Quick Ratio4.76
Price-To-Earnings
Trailing P/E Ratio4,097.00
Forward P/E Ratio455.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$90.61 million
Price / Sales19.95
Cash Flow$0.0870 per share
Price / Cash470.93
Book Value$2.92 per share
Price / Book14.03
Profitability
EPS (Most Recent Fiscal Year)$0.01
Net Income$-2,130,000.00
Net Margins3.17%
Return on Equity14.80%
Return on Assets10.15%
Miscellaneous
Employees353
Outstanding Shares44,130,000
Market Cap$1.90 billion
OptionableOptionable
